Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
The Latest on: Type 1 diabetes
via Google News
The Latest on: Type 1 diabetes
- Pediatric diabetes cases on the rise in Hawaiion November 30, 2020 at 1:08 am
November is Diabetes Awareness Month and health experts say prevalence of pediatric cases is on the rise. Nurse practitioner Eludrizza Tabisola-Nuesca at Pediatric Endocrinology at Kapiolani Medical ...
- NHS Thumbs Up to CGM for Pregnant Type 1 Diabetes Patientson November 25, 2020 at 8:55 am
As CGM is made available for type 1 diabetes pregnancies in the UK, an audit has underscored the association between raised A1c levels and poor outcomes in all pregnant patients with diabetes.
- Drug lets kids with type 1 diabetes produce insulinon November 24, 2020 at 9:01 am
Kids and young adults newly diagnosed with type 1 diabetes who took a drug called golimumab were able to produce their own insulin a year later.
- IBM claims its AI can improve neonatal outcomes and predict the onset of Type 1 diabeteson November 20, 2020 at 8:50 pm
IBM researchers claim to have developed machine learning algorithms that can improve neonatal outcomes and predict Type 1 diabetes onset.
- Golimumab for Type 1 Diabetes; Long-Term Success for Oral Octreotideon November 20, 2020 at 11:36 am
Oral octreotide (Mycapssa) was noninferior to long-acting injectables, maintaining IGF-1 response in 91% of patients with acromegaly over 9 months, Chiasma announced. More evidence supporting the ...
- Newton South senior chosen as role model for those with Type 1 diabeteson November 19, 2020 at 10:54 am
Noa Asher, 17, was honored as the Merritt Levitan Youth Ambassador at the Joslin Diabetes Center’s High Hopes Gala.
- Study finds young patients newly diagnosed with Type 1 diabetes still produce insulin with golimumabon November 19, 2020 at 4:46 am
The UB-led study of kids and young adults newly diagnosed with Type 1 diabetes was published in The New England Journal of Medicine.
- UB-led study shows off-label drug extends insulin production for those with Type 1 diabeteson November 18, 2020 at 1:14 pm
A University at Buffalo pediatric endocrinologist's clinical trial found that an 11-year-old drug used to treat other autoimmune conditions can preserve insulin-making power for at least a year in som ...
- Managing Type 1 Diabetes Postpartum: Self-Care After Baby Arriveson November 16, 2020 at 6:28 am
Pregnancy with type 1 diabetes is no walk in the park. In fact, for many women, it may be the most challenging diabetes management phase of your life. Fortunately, it’s remarkably rewarding ...
- What Is Type 1 Diabetes? Symptoms, Causes, Diagnosis, and Treatmenton November 15, 2020 at 4:00 pm
(2) With type 1 diabetes, the body’s immune system attacks and destroys the pancreas’s insulin-producing beta cells. Without that hormone, blood sugar rises too high, causing hyperglycemia.
via Bing News